CHP-753, Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL).

Trial Profile

CHP-753, Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2013

At a glance

  • Drugs Sirolimus (Primary) ; Cyclophosphamide; Methotrexate; Tacrolimus; Thiotepa
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 May 2012 Actual patient number changed from 10 to 63 as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top